Clinical studies designed to support FDA clearance and planned commercial launch into the world’s largest drug screening market Company anticipates…
Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel Approach to Targeted, Pressure-Mediated Drug-Delivery via Additional Clinical DataMOUNTAIN…
WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to…
Company ready to commence regulatory process to secure access to U.S. market for Australian Chestnut Extract as a botanical product…
Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the…
-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026…
• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’…
- TRPML1 is a promising target1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement in…
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trialsBOSTON, Jan. 28,…
Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and…